Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma

Neoplasma

Volumn 53, Issue 3, 2006, Pages 213-218

  Scudla, V ^a   Ordeltova, M ^a   Minarik, J ^a   Dusek, L ^b   Zemanova, M ^a   Bacovsky, J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Annexin V index; Apoptosis; Multiple myeloma; Overall kinetic index of plasma cells; Plasma cell; Prognosis; Propidium iodide index

Indexed keywords

DNA; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE; SYNDECAN 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; STAINING; STATISTICAL SIGNIFICANCE;

EID: 33744904238     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. LANDOWSKI TH, DALTON WS. Molecular biology of plasma cell disorders. In: Mehta J, Singhal S, editors. Myeloma. London: Martin Dunitz, 2002: 25-37.
2. ZHANG B, GOJO I, FENTON RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893.
3. 2-micro-globulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382-3387.
4. BOCCADORO M, MARMONT F, TRIBALTO M, FOSSATI G, REDOGLIA v et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 1989; 7: 119-125.
5. JOSHUA D, PETERSEN A, BROWN R, POPE B, SNOWDON L, GIBSON J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Brit J Haematol 1996; 64: 76-81.
6. SAN MIGUEL JF, GARCÍA-SANZ R, GONZÁLEZ M, MORO MJ, HERNANDEZ JM et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-455.
7. SCUDLA V, BACOVSKY J, VYTRASOVA M, ORDELTOVA M, PAPAJIK T, OPICHALOVA D. Prognostic factors and clinical staging systems in multiple myeloma in the group of 237 patients from the years 1991-2002 treated with conventional therapy I. Prognostic significance of selected clinical and laboratory markers. II. Prognostic significance of some existing staging systems. Klin Onkol (Brno) 2002; 15 Suppl 1: 7-14, 15-20.
8. TRENDLE MC, LEONG T, KYLE RA, KATZMANN JA, OKEN MM et al. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. Am J Hematol 1999; 61: 232-237.
9. WITZ̀IG TE, TIMM M, LARSON D, THERNEAU T, GREIPP PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Brit J Haematol 1999; 104: 131-137.
10. XU JL, LAI R, KINOSHITA T, NAKASHIMA N, NAGASAKA T. Proliferation apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-534.
11. SWOG Southwest Oncology Group. Remission maintenance therapy for multiple myeloma. Arch Int Med 1975; 135: 147-152.
12. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
13. 4) recognize syndecan-1. Brit J Haematol 1996; 94: 318-323.
14. 138/propidium iodide index) of myeloma cells using flow cytometry. Diagnoza 1999; 1: 12-15.
15. 38/propidium iodide double staining technique. Cytometry 1994; 17: 332-339.
16. SCUDLA V, ORDELTOVA M, SPIDLOVA A, BACOVSKY J, KURASOVA J, VRANOVA V. Importance of examination of the propidium-iodide index of plasmocytes in multiple myeloma. I. Relationship to some laboratory findings of the disease. II. Relationship with extent and activity of the disease. Vnitr Lek 1999; 45: 331-335, 336-341.
17. SCUDLA V, ORDELTOVA M, BACOVSKY J, VYTRASOVA M, SUMNA E et al. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Neoplasma 2003; 50: 363-371.
18. 2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98: 2183-2192.
19. BATAILLE R. A cellular model for myeloma cell growth and differentiation. Hematol J 2002; 3 Suppl 2: 48.
20. 2-microglobulin. Hematopathology 1996; 106: 64-68.
21. 2-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica 1999; 84: 905-910.
22. CALIGARIS-CAPPIO F. Biology of the malignant plasma cell. In: Gahrton G, Durie BGM, Samson DM, editors. Multiple myeloma and related disorders. London: Arnold, 2004: 58-73.
23. GREIPP PR, WITZIG TE, GONCHOROFF NJ, HABERMANN TM, KATZMANN JA, O'FALLON WM. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987; 62: 969-977.
24. STEENSMA DP, GERTZ MA, GREIPP PR, KYLE RA, LACY MQ, LUST JA et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001; 97: 2522-2523.
25. LOKHORST HM, BOOM SE. BAST BE. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Brit J Haematol 1986; 64: 271-275.
26. VACCA A, RIBATTI D, RONCALI L, DAMMACCO F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymph 1995; 20: 27-38.
27. DREWINKO B, ALEXANIAN R, BOYER H, BARLOGIE B, RUBINOW SI. The growth fraction of human myeloma cells. Blood 1981; 57: 333-338.
28. GARCIA-SANZ R, ORFAO A, GONZALEZ M. MORO JM, HERNÁNDEZ JM et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br J Haematol 1995; 90: 106-112.
29. JOSHUA DE, SNOWDON L, GIBSON J, ILAND H, BROWN R et al. Multiple myeloma: plateau phase revisited. Haematol Rev Comm 1991; 5: 59-66.
30. GREIPP PR, KYLE RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983; 62: 166-171.
31. RAJKUMAR SV, FONSECA R, DEWALD GW, THERNEAU TM, LACY MQ et al. Cytogenetic abnormalitis correlate with the plasma cell labeling index and extent for bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-77.
32. KYLE RA. Multiple myeloma. Diagnostic challenges and standard therapy. Sem Hematol 2001; 38 Suppl 3: 11-14.
33. KLUCK RM, BOSSY-WETZEL E, GREEN DR, NEWMEYER DD. The release of cytochrome-c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
34. LANDOWSKI TH, QU N, BUYUKSAL I, PAINTER JS, DALTON WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-4270.
35. STECK K, MCDONNELL T, SNEIGE N, EL-NAGGAR A. Flow cytometric analysis of apoptosis and BCL-2 in primary breast carcinomas: clinical and biological implications. Cytometry 1996; 24: 116-122.
36. 95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Brit J Haematol 1997; 97: 418-428.
37. PUTHIER D, PELLAT-DECEUNYNCK C, BARILLE S, ROBILLARD N, RAPP MJ et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999; 13: 289-294.
38. YANG J, LIU X, BHALLA K, KIM CN, IBRADO AM et al. Prevention of apoptosis by BCL-2: release of cytochrome-c from mitochondria blocked. Science 1997; 275: 1129-1132.
39. LANDOWSKI T, GLEASON-GUZMAN M, DALTON W. Selection for drug resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-1861.
40. KOOPMAN G, REUTELINGSPERGER CPM, KUIJTEN GAM, KEEHNEN RMJ, PALS ST, VAN OERS MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.